CytomX Therapeutics, Inc.

CytomX Therapeutics Beats on EPS, Stock Up 0.79%

CytomX Therapeutics reported a positive surprise in EPS, which contributed to a slight increase in stock price. However, there was no revenue reported, and no guidance was provided, leaving investors without a clear outlook for the future. The stock's modest gain reflects a positive reaction to the earnings surprise, despite the lack of additional information.